Treatment of Large and Advanced Hepatocellular Carcinoma
详细信息 查看全文
- 作者：Eddie K. Abdalla MD (1)
Alban Denys MD (2)
Kiyoshi Hasegawa MD (3)
Thomas W. T. Leung MD (4)
Masatoshi Makuuchi MD ; PhD (3)
Ravi Murthy MD (5)
Dario Ribero MD (1)
Daria Zorzi MD (1)
Jean-Nicolas Vauthey MD (1)
Guido Torzilli MD ; PhD (6) - 关键词：HCC ; Large ; Multinodular ; Advanced ; Chemoembolization ; Microsphere ; Systemic therapy
- 刊名：Annals of Surgical Oncology
- 出版年：2008
- 出版时间：April 2008
- 年：2008
- 卷：15
- 期：4
- 页码：979-985
- 全文大小：227KB
- 参考文献：1. Mazzaferro V, Regalia E, Doci R, et聽al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693鈥? 10.1056/NEJM199603143341104">CrossRef
2. Lo CM, Ngan H, Tso WK, et聽al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164鈥?1 10.1053/jhep.2002.33156">CrossRef
3. Llovet JM, Bustamante J, Castells A, et聽al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62鈥? 10.1002/hep.510290145">CrossRef
4. Pawlik TM, Delman KA, Vauthey JN, et聽al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11:1086鈥?2 10.1002/lt.20472">CrossRef
5. Vauthey JN, Lauwers GY, Esnaola NF, et聽al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527鈥?6 10.1200/JCO.20.6.1527">CrossRef
6. Jonas S, Bechstein WO, Steinmuller T, et聽al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080鈥? 10.1053/jhep.2001.23561">CrossRef
7. Pawlik TM, Poon RT, Abdalla EK, et聽al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140:450鈥? 10.1001/archsurg.140.5.450">CrossRef
8. Liu CL, Fan ST, Cheung ST, et聽al. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006; 244:194鈥?03 10.1097/01.sla.0000225095.18754.45">CrossRef
9. Belghiti J, Guevara OA, Noun R, et聽al. Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization. J Am Coll Surg 2001; 193:109鈥?1 10.1016/S1072-7515(01)00909-7">CrossRef
10. Ogata S, Belghiti J, Varma D, et聽al. Two hundred liver hanging maneuvers for major hepatectomy: a single-center experience. Ann Surg 2007; 245:31鈥? 10.1097/01.sla.0000224725.40979.0a">CrossRef
11. Yoshioka H, Sato M, Sonomura T, et聽al. Factors associated with survival exceeding 5聽years after transcatheter arterial embolization for hepatocellular carcinoma. Semin Oncol 1997; 24:S6鈥?9鈥揝26鈥?7
12. O鈥橲uilleabhain CB, Poon RT, Yong JL, et聽al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003; 90:325鈥?1 10.1002/bjs.4045">CrossRef
13. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002; 8:736鈥?8 10.1053/jlts.2002.34879">CrossRef
14. Figueras J, Jaurrieta E, Valls C, et聽al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25:1485鈥?9 10.1002/hep.510250629">CrossRef
15. Hemming AW, Cattral MS, Reed AI, et聽al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233:652鈥? 10.1097/00000658-200105000-00009">CrossRef
16. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21:4329鈥?5 10.1200/JCO.2003.11.137">CrossRef
17. Yamamoto J, Iwatsuki S, Kosuge T, et聽al. Should hepatomas be treated with hepatic resection or transplantation? Cancer 1999; 86:1151鈥?8 10.1002/(SICI)1097-0142(19991001)86:7<1151::AID-CNCR8>3.0.CO;2-V">CrossRef
18. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10:S115鈥?0 10.1002/lt.20034">CrossRef
19. Nagasue N, Kohno H, Chang YC, et聽al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11聽years. Ann Surg 1993; 217:375鈥?4 10.1097/00000658-199304000-00009">CrossRef
20. Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin North Am 2003; 12:35鈥?0, viii 10.1016/S1055-3207(02)00086-8">CrossRef
21. Vauthey JN, Klimstra D, Franceschi D, et聽al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28鈥?4 10.1016/S0002-9610(99)80106-8">CrossRef
22. Ng KK, Vauthey JN, Pawlik TM, et聽al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005; 12:364鈥?3 10.1245/ASO.2005.06.004">CrossRef
23. Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis 1986; 6:259鈥?6 10.1055/s-2008-1040608">CrossRef
24. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001; 233:379鈥?4 10.1097/00000658-200103000-00012">CrossRef
25. Groupe d鈥橢tude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256鈥?1 10.1056/NEJM199505113321903">CrossRef
26. Llovet JM, Real MI, Montana X, et聽al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734鈥? 10.1016/S0140-6736(02)08649-X">CrossRef
27. Takayasu K, Arii S, Ikai I, et聽al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461鈥? 10.1053/j.gastro.2006.05.021">CrossRef
28. Llad贸 L, Virgili J, Figueras J, et聽al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88:50鈥? 10.1002/(SICI)1097-0142(20000101)88:1<50::AID-CNCR8>3.0.CO;2-I">CrossRef
29. Pacella CM, Bizzarri G, Cecconi P, et聽al. Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology 2001; 219:669鈥?8
30. Veltri A, Moretto P, Doriguzzi A, et聽al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16:661鈥? 10.1007/s00330-005-0029-9">CrossRef
31. Wu F, Wang ZB, Chen WZ, et聽al. Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology 2005; 235:659鈥?7 10.1148/radiol.2352030916">CrossRef
32. Raoul JL, Guyader D, Bretagne JF, et聽al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine鈥?31-iodized oil versus medical support. J Nucl Med 1994; 35:1782鈥?
33. Uraki J, Yamakado K, Nakatsuka A, Takeda K. Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. Eur J Radiol 2004; 51:12鈥? 10.1016/S0720-048X(03)00219-5">CrossRef
34. Obi S, Yoshida H, Toune R, et聽al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106:1990鈥? 10.1002/cncr.21832">CrossRef
35. Houle S, Yip TK, Shepherd FA, et聽al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989; 172:857鈥?0
36. Shepherd FA, Rotstein LE, Houle S, et聽al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992; 70:2250鈥? 10.1002/1097-0142(19921101)70:9<2250::AID-CNCR2820700906>3.0.CO;2-4">CrossRef
37. Andrews JC, Walker SC, Ackermann RJ, et聽al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35:1637鈥?4
38. Dancey JE, Shepherd FA, Paul K, et聽al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41:1673鈥?1
39. Lau WY, Leung WT, Ho S, et聽al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994; 70:994鈥?
40. Lau WY, Ho S, Leung TW, et聽al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40:583鈥?2
41. Carr BI. Hepatic arterial 90 yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10:S107鈥?0 10.1002/lt.20036">CrossRef
42. Geschwind JF, Salem R, Carr BI, et聽al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127:S194鈥?05 10.1053/j.gastro.2004.09.034">CrossRef
43. Lau WY, Ho S, Leung WT, et聽al. What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres? Hepatogastroenterology 2001; 48:338鈥?0
44. Goin JE, Salem R, Carr BI, et聽al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16:205鈥?3
45. Salem R, Lewandowski RJ, Atassi B, et聽al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627鈥?9
46. Goin J, Roberts C. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: Trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nuc Med 2004; 49鈥?6
47. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001; 28:514鈥?0 10.1016/S0093-7754(01)90144-7">CrossRef
48. Yeo W, Mok TS, Zee B, et聽al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97:1532鈥? 10.1093/jnci/dji315">CrossRef
49. Lau WY, Leung TW, Lai BS, et聽al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001; 233:236鈥?1 10.1097/00000658-200102000-00013">CrossRef
50. Leung TW, Tang AM, Zee B, et聽al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94:421鈥? 10.1002/cncr.10236">CrossRef
51. Llovet J, Ricci S, Mazzaferro V, et聽al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25:LBA1
52. Abou-Alfa GK, Schwartz L, Ricci S, et聽al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293鈥?00 10.1200/JCO.2005.01.3441">CrossRef - 作者单位：Eddie K. Abdalla MD (1)
Alban Denys MD (2)
Kiyoshi Hasegawa MD (3)
Thomas W. T. Leung MD (4)
Masatoshi Makuuchi MD, PhD (3)
Ravi Murthy MD (5)
Dario Ribero MD (1)
Daria Zorzi MD (1)
Jean-Nicolas Vauthey MD (1)
Guido Torzilli MD, PhD (6)
1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
2. Department of Diagnostic and Interventional Radiology, Centre Hospitalier-Universitaire Vaudois, Lausanne, Switzerland
3. Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
4. Comprehensive Oncology Center, Hong Kong Sanatorium & Hospital, Hong Kong, China
5. Interventional Radiology Section, Division of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
6. Liver Surgery Unit, 3rd Department of Surgery, Istituto Clinico Humanitas-IRCCS, University of Milan, Faculty of Medicine, Via A. Manzoni 56, Rozzano Milan, 1-20147, Italy
文摘